Sequencing Treatment for Castration-Resistant Prostate Cancer

被引:0
作者
Catherine E. Handy
Emmanuel S. Antonarakis
机构
[1] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
[2] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,undefined
来源
Current Treatment Options in Oncology | 2016年 / 17卷
关键词
Prostate cancer; Metastatic castration-resistant prostate cancer; Treatment sequence;
D O I
暂无
中图分类号
学科分类号
摘要
Prostate cancer is the most common non-cutaneous cancer diagnosed in men and the second leading cause of male cancer deaths in the USA. While most cases are diagnosed in early stages, some will present as or progress to metastatic disease and eventually castration-resistant prostate cancer (mCRPC) which has a mortality rate exceeding 50 %. There are currently six approved systemic life-prolonging therapies for use in mCRPC, yet little data to guide sequencing. Clinical factors, including the presence or absence of symptoms and the presence or absence of visceral metastases, should help determine the best therapeutic choice at each treatment node. Those with asymptomatic bone-only disease could be considered for sipuleucel-T, abiraterone, enzalutamide, or docetaxel in the first-line setting. For symptomatic disease, docetaxel could be used or radium-223 if disease is only present in the bone. In the second-line setting, sipuleucel-T or radium-223 can be used in the appropriate clinical setting. Taxane chemotherapy could be used if a novel androgen-directed therapy was used in the first-line setting. Cabazitaxel, if docetaxel was previously used, should be considered. There is scarce data on best treatment options in the third-line setting. In general, we recommend alternating between androgen-targeting agents and taxane chemotherapy. Finally, consideration should be given to testing for the androgen receptor splice variant AR-V7, which may be a relevant treatment-specific biomarker to aid in the selection of androgen-targeting therapy versus chemotherapy at each treatment juncture. Mutation testing for DNA damage repair defects can also be considered, as such patients may benefit from investigational poly ADP ribose polymerase (PARP) inhibitors or platinum-based chemotherapies. Several ongoing studies have been designed to answer some of these sequencing questions, including the biomarker questions, and will hopefully continue to inform us about rational therapy selection in mCRPC.
引用
收藏
相关论文
共 597 条
[1]  
Brawley OW(2012)Trends in prostate cancer in the United States J Natl Cancer Inst Monogr 2012 152-156
[2]  
Scher HI(2015)Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model PLoS One 10 e0139440-244
[3]  
Solo K(2005)Androgen deprivation therapy for prostate cancer JAMA 294 238-1418
[4]  
Valant J(2016)Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 J Clin Oncol 34 1402-245
[5]  
Todd MB(2008)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 242-1512
[6]  
Mehra M(2004)Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1502-1520
[7]  
Sharifi N(2004)Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513-2005
[8]  
Gulley JL(2011)Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 1995-1197
[9]  
Dahut WL(2012)Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 1187-160
[10]  
Scher HI(2015)Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 16 152-433